Suppr超能文献

睾丸癌男性的生育力保存:在辅助生殖技术时代,精子冷冻保存是否具有成本效益?

Fertility preservation for men with testicular cancer: Is sperm cryopreservation cost effective in the era of assisted reproductive technology?

作者信息

Gilbert Kirven, Nangia Ajay K, Dupree James M, Smith James F, Mehta Akanksha

机构信息

Department of Urology, Emory University School of Medicine, Atlanta, GA.

Department of Urology, University of Kansas Medical Center, Kanas City, KS.

出版信息

Urol Oncol. 2018 Mar;36(3):92.e1-92.e9. doi: 10.1016/j.urolonc.2017.11.002. Epub 2017 Nov 21.

Abstract

INTRODUCTION

Many patients do not cryopreserve sperm before undergoing cancer treatment because of high perceived costs of cryopreservation. We sought to investigate the cost-effectiveness of fertility preservation compared to posttherapeutic fertility treatment in testicular cancer patients.

MATERIALS AND METHODS

We performed a systematic search of the PubMed database for the following: risk of azoospermia 12 months after surveillance, chemotherapy, retroperitoneal lymph node dissection, and radiation therapy (RT); rates of natural conception, and rates of conception with the use of intrauterine insemination or assisted reproductive technology, with or without microsurgical testicular sperm extraction (microTESE). A decision tree was constructed using the TreePlan add-in for Microsoft Excel (TreePlan Software, San Francisco, California). Cost-effectiveness was calculated as the overall cost of a given management branch, divided by likelihood of pregnancy. Calculations accounted for variable number of years of cryopreservation, and variable costs of microTESE.

RESULTS

1,113 articles were identified; 44 were included in the final analysis. Overall probability of pregnancy was higher among couples who cryopreserved sperm, versus those who did not. In patients undergoing active surveillance or retroperitoneal lymph node dissection, cryopreservation was more cost-effective if storage time was short (<6 years) or microTESE cost was high (>7,000). Cryopreservation prior to chemotherapy was more cost-effective unless microTESE cost was low (<7,000). Cryopreservation prior to RT was more cost-effective in almost all scenarios.

CONCLUSIONS

Sperm cryopreservation prior to undergoing chemotherapy or RT remains the most cost-effective strategy for fertility preservation, across a range of possible costs associated with surgical sperm retrieval and in vitro fertilization/intracytoplasmic sperm injection.

摘要

引言

许多患者在接受癌症治疗前未进行精子冷冻保存,因为他们认为冷冻保存成本过高。我们试图研究与睾丸癌患者治疗后的生育治疗相比,生育力保存的成本效益。

材料与方法

我们对PubMed数据库进行了系统检索,内容如下:监测、化疗、腹膜后淋巴结清扫和放射治疗(RT)后12个月无精子症的风险;自然受孕率,以及使用宫内人工授精或辅助生殖技术(无论是否进行显微外科睾丸精子提取(microTESE))的受孕率。使用适用于Microsoft Excel的TreePlan加载项(TreePlan软件,加利福尼亚州旧金山)构建决策树。成本效益计算为给定管理分支的总成本除以怀孕可能性。计算考虑了不同的冷冻保存年限以及microTESE的可变成本。

结果

共识别出1113篇文章;最终分析纳入了44篇。冷冻保存精子的夫妇的总体怀孕概率高于未冷冻保存精子的夫妇。在接受主动监测或腹膜后淋巴结清扫的患者中,如果储存时间较短(<6年)或microTESE成本较高(>7000),冷冻保存更具成本效益。化疗前进行冷冻保存更具成本效益,除非microTESE成本较低(<7000)。在几乎所有情况下,放疗前进行冷冻保存更具成本效益。

结论

在与手术取精和体外受精/卵胞浆内单精子注射相关的一系列可能成本范围内,化疗或放疗前进行精子冷冻保存仍然是生育力保存最具成本效益的策略。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验